$223.91
1.51% day before yesterday
NYSE, Sep 06, 10:10 pm CET
ISIN
US50540R4092
Symbol
LH

Laboratory Stock price

$223.91
-1.96 0.87% 1M
+6.11 2.81% 6M
-3.38 1.49% YTD
+19.31 9.44% 1Y
-39.52 15.00% 3Y
+75.35 50.72% 5Y
+131.02 141.04% 10Y
NYSE, Closing price Fri, Sep 06 2024
-3.43 1.51%
ISIN
US50540R4092
Symbol
LH
Sector

Key metrics

Market capitalization $18.80b
Enterprise Value $24.53b
P/E (TTM) P/E ratio 42.52
EV/FCF (TTM) EV/FCF 28.78
EV/Sales (TTM) EV/Sales 1.96
P/S ratio (TTM) P/S ratio 1.51
P/B ratio (TTM) P/B ratio 2.34
Dividend yield 1.20%
Last dividend (FY23) $2.68
Revenue growth (TTM) Revenue growth -11.38%
Revenue (TTM) Revenue $12.49b
EBIT (operating result TTM) EBIT $1.13b
Free Cash Flow (TTM) Free Cash Flow $852.30m
Cash position $265.10m
EPS (TTM) EPS $5.27
P/E forward 20.92
P/S forward 1.45
EV/Sales forward 1.89
Short interest 2.65%
Show more

Is Laboratory a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Laboratory Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Laboratory forecast:

12x Buy
67%
6x Hold
33%

Analyst Opinions

18 Analysts have issued a Laboratory forecast:

Buy
67%
Hold
33%

Financial data from Laboratory

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
12,488 12,488
11% 11%
100%
- Direct Costs 9,229 9,229
12% 12%
74%
3,259 3,259
9% 9%
26%
- Selling and Administrative Expenses 1,474 1,474
11% 11%
12%
- Research and Development Expense - -
-
-
1,785 1,785
21% 21%
14%
- Depreciation and Amortization 651 651
17% 17%
5%
EBIT (Operating Income) EBIT 1,135 1,135
24% 24%
9%
Net Profit 450 450
46% 46%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Laboratory directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Laboratory Stock News

Neutral
PRNewsWire
4 days ago
BURLINGTON, N.C. , Sept. 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 3:10 p.m.
Positive
Reuters
13 days ago
Diagnostics firm Labcorp said it is processing approximately 500 mpox tests a month but have the capacity to process approximately 25,000 per month.
Neutral
PRNewsWire
about one month ago
Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C. , Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company.
More Laboratory News

Company Profile

Laboratory Corp. of America Holdings is a clinical laboratory company. The firm engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the following segments: LabCorp Diagnostics and Covance Drug Development. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment provides drug development solutions to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.

Head office United States
CEO Adam Schechter
Employees 67,000
Founded 1971
Website www.labcorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today